 Dividend.com | CORRECT: Sales forecast haunts Abbott shares MarketWatch By Val Brickates Kennedy, MarketWatch BOSTON (MarketWatch) - Abbott Laboratory shares moved notably lower Wednesday as investors reacted negatively to news that sales growth for the company's popular rheumatoid arthritis drug Humira might not be as ... Abbott Revenue Misses Estimates on Generics, Economy Sales of Abbott's Humira Shy Of Projections Abbott Lab Q1 profit rises; Guides Q2, Backs FY09 EPS outlook ... |
Source: news.google.com
No comments:
Post a Comment